This analysis may not only be useful as a novel diagnosis biomarker of neurodegenerative and cerebrovascular diseases but it may also help to distinguish patients with PD (with lower 5hmC levels and no changes in DNMT3a expression) from AD or DV. Here, DNMT3A is linked to Alzheimer disease.